YAP1 and sarcoma: To confirm this is the case in sarcomas, we performed targeted PCR-based Sanger sequencing of 12 sarcoma cell lines and GCT (giant cell tumor) for the presence of mutations in the serines in TAZ (S66, 89, 117, and 311) [46] and YAP (S61, 109, 127, 164, and 381) [2] phosphorylated by LATS1/2.